Skip to main content

Table 1 Patient characteristics and mortality

From: Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock

 

GCS ≥ 13

GCS <13

Gender (M/F; n)

12/11

21/10

Age (years; mean ± SD)

69 ± 13

72 ± 10

APACHE II score (mean ± SD)

17 ± 4 *

25 ± 7

Baseline SOFA score (mean ± SD)

8 ± 2 *

10 ± 3

Baseline S100B (μg/L; mean ± SEM)

0.70 ± 0.08°

0.96 ± 0.15

ICU mortality (n; %)

  

   DrotAA

6 (67)

10 (67)

   No DrotAA

7 (50)

9 (56)

Hospital mortality (n; %)

  

   DrotAA

6 (67)

13 (86)

   No DrotAA

10 (71)

12 (75)

  1. * P < 0.05, °P = 0.05 as compared to patients with GCS <13
  2. number and percentage of DrotAA-treated or -untreated patients who died
  3. APACHE: Acute Physiology and Chronic Health Evaluation; DrotAA: drotrecogin alfa (activated); F: female; ICU: intensive care unit; M: male; SOFA: Sequential Organ Failure Assessment